Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.32 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piperazine SCHEMBL25363735 | 0.84 | CA1 (0.39) | LMNACYP3A4GABRA1TSHRGABRG2 | |
| SCHEMBL30722804 | 0.82 | LMNA (0.31) | LMNACYP3A4GABRA1TSHRGABRG2 | |
| SCHEMBL27349106 | 0.82 | LMNA (0.38) | LMNACYP3A4GABRA1TSHRGABRG2 | |
| SCHEMBL11027150 | 0.80 | MEN1 (0.36) | SIGMAR1KDM4EKMT2A | |
| SCHEMBL11027147 | 0.80 | SMN1; SMN2 (0.33) | SIGMAR1 | |
| Pyrrolidine SCHEMBL28002045 | 0.79 | CA1 (0.34) | LMNACYP3A4GABRA1TSHRGABRG2 | |
| Piperidine SCHEMBL27604638 | 0.79 | ALDH1A1 (0.38) | LMNACYP3A4GABRA1TSHRGABRG2 | |
| SCHEMBL29117322 | 0.78 | SMN1; SMN2 (0.33) | SIGMAR1 | |
| SCHEMBL11204885 | 0.78 | TSHR (0.42) | LMNACYP3A4TSHRKMT2A | |
| Morpholine SCHEMBL5973028 | 0.76 | MEN1 (0.41) | TSHRCA1CA2KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7101676-B2 | Methods for identifying compounds which inhibit binding of nucleocapsid 7 protein to HIV-1 RNA | ACHILION PHARMACEUTICALS | 2006-09-05 | — | — | US | disclosed |
| US-20030198648-A1 | Methods for identifying compounds which inhibit binding of nucleocapsid 7 protein to HIV-1 RNA | ACHILION PHARMACEUTICALS | 2003-10-23 | — | — | US | disclosed |
| WO-2003060098-A2 | METHODS FOR IDENTIFYING COMPOUNDS WHICH INHIBIT BINDING OF NUCLEOCAPSID 7 PROTEIN TO HIV-1 RNA | ACHILLION PHARMACEUTICALS, INC. (US) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030198648-A1 | Methods for identifying compounds which inhibit binding of nucleocapsid 7 protein to HIV-1 RNA | MRPS27, SNRPE, NSUN2 | LMNA 2733/4885CYP3A4 4653/4885GABRA1 4157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.